CELL INTELLIGENCE · 肿瘤细胞治疗研究

FATP2 介导的脂质代谢增强 B 细胞急性淋巴细胞白血病中 CAR-T 细胞治疗的耐药

FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia.

整合素α4 抑制可延长移植 CD19 阴性 CAR-T19 后复发 B-ALL 的 NSG 小鼠的生存期

Integrin Alpha 4 Inhibition Prolongs the Survival of NSG Mice Engrafted with CD19-Negative Post-CART19 Relapsed B-ALL.

CAR 疗法在肿瘤与自身免疫领域的演进：机制见解与治疗创新

The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations.

利用 CD2 轴拓宽并增强 CAR-T 细胞疗法的疗效

Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.

通过平铺碱基编辑的等位基因读出进行调控元件的核苷酸分辨率定位

Nucleotide-resolution mapping of regulatory elements via allelic readout of tiled base editing.

在 CD19xCD22 CAR-T 细胞中，双重 CAR 刺激导致的 NFAT 活性增加与耗竭减少和生存改善相关

Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival.

在 CD19xCD22 双顺反子 CAR 构建体中，同时刺激两个 CAR 分子会影响 CAR-T 细胞内的下游信号事件，并随后驱动更有效的体内反应，持续存在的细胞中表现出耗竭减少的证据。这些数据表明，双顺反子 CAR 平台不仅具有靶向两种抗原以防止抗原调制逃逸的潜力，还可以通过工程化改造来改善 CAR-T 细胞生物学的多个方面，例如减轻耗竭，从而克服当前 CAR-T 细胞疗法中已知驱动复发的多种机制。

靶向 CCR5 的同种异体 γδ CD19 CAR-T 细胞用于 HIV 相关 B 细胞恶性肿瘤免疫治疗

CCR5-targeted allogeneic gamma-delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy.

通过非病毒工程与高度多重碱基编辑精准增强 CAR-NK 细胞

Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing.

CAR-T 细胞治疗的进展：抗原选择、改造及实体瘤当前试验

Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors.

利用碱基编辑筛选绘制变异对原代人 T 细胞抗肿瘤特征的影响

Mapping variant effects on anti-tumor hallmarks of primary human T cells with base-editing screens.